好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Guillain-Barre Syndrome after Influenza Vaccination in Adults
Neuro Trauma and Critical Care
P12 - Poster Session 12 (5:30 PM-6:30 PM)
1-006

To investigate the association of Guillain-Barre syndrome (GBS) after administration of influenza vaccine in the United States.

GBS was reported after receiving influenza vaccination.
Data from the Vaccine Adverse Event Reporting System (VAERS) from 1989-2021 was used. GBS data was ascertained using Brighton criteria. Self-controlled case series analysis and case-centered analysis were used. Six weeks after vaccination was defined as the risk period of probable cause-effect.
From 1989 to 2021, 3285 cases (mean age 47 years) of GBS fulfilling Brighton criteria and 663 cases that did not fulfill Brighton criteria were reported. The reporting rate of GBS after influenza vaccination was 0.09 per million. Among the patients fulfilling Brighton criteria, 82.1% developed GBS within 6 weeks and 17.9% after 6 weeks. The distribution of GBS within the first 6 weeks after vaccination was unbalanced: 59.4% of GBS cases were reported within the first two weeks with a peak in the first week after vaccination. Hospitalization and disability were reported in 9.6% and 19.2% cases, respectively. GBS occurred in 54.2% cases when the influenza vaccine was administrated as a single vaccine and in 0.8% cases when combined with other vaccines. Using self-controlled and case centered analyses, there was a significant difference in the reporting rate of GBS after influenza vaccination between the risk period and control period (86.8% vs 2.2-7.1%, p<0.00001).
There is no significant increase in the reporting rate of GBS after vaccination. Although, our results suggest that the reporting rate of GBS post-influenza vaccine overlaps with the incidence of GBS in the general population, the unbalanced distribution of reported cases in the first 6 weeks after vaccination and the increased reporting rate in the risk time period compared to the control time period may suggest that some cases of GBS are associated with influenza vaccine.
Authors/Disclosures

PRESENTER 		No disclosure on file
Mustafa Jaffry Mr. Jaffry has nothing to disclose.
Kranthi K. Mandava Mr. Mandava has nothing to disclose.
Kazim Jaffry Mr. Jaffry has nothing to disclose.
Jorge L. Rodriguez Lee, MD (Yale School of Medicine) Dr. Rodriguez Lee has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Ayatalla Ahmed, MBBS Dr. Ahmed has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Nizar Souayah, MD, FAAN (NJMS) Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.